CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
化疗诱导的 ciltacabtagene autoleucel 相关运动与神经认知毒性的逆转
英文原题：Chemotherapy-induced reversal of ciltacabtagene autoleucel-associated movement and neurocognitive toxicity.
查看英文原题
Chemotherapy-induced reversal of ciltacabtagene autoleucel-associated movement and neurocognitive toxicity.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
在2篇发表于Blood的互补通讯中，Karschnia等和Graham等对多发性骨髓瘤BCMA靶向CAR-T 治疗中观察到的神经毒性提供了新见解，发现免疫效应细胞相关神经毒性综合征（ICANS）的发生率超过40%。在这一真实世界系列中，8%的患者出现重度ICANS。结局总体良好，尽管作者描述了2例患者在ICANS后出现罕见的迟发性帕金森样运动减少性运动障碍（也称为运动和神经认知毒性）。
展开英文摘要原文
In 2 complementary Letters to Blood, Karschnia et al and Graham et al provide new insights into the neurological toxicities that are observed with B-cell maturation antigen–directed chimeric antigen receptor T-cell treatment for multiple myeloma, identifying a frequency of immune effector cell–associated neurotoxicity syndrome (ICANS) that exceeds 40%.
Severe ICANS is identified in 8% of patients in this real-world series. Outcomes were generally favorable, although the authors describe rare, late Parkinsonism-like hypokinetic movement disorders (also known as movement and neurocognitive toxicities) post-ICANS in 2 patients.
论文信息
- 作者
- Graham CE、Lee WH、Wiggin HR、Supper VM、Leick MB、Birocchi F、Yee AJ、Petrichenko A
- 单位
- Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA.United States
- 期刊
- Blood2023 Oct 5
- 原文标识
- PubMed 37467494 · DOI 10.1182/blood.2023021429
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →